Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
نویسندگان
چکیده
Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival to characterize prognostic factors affecting metastatic castration-resistant prostate cancer (mCRPC) patients. A total 250 patients treated with E or AA 5 centers were included. The number no specific antigen (PSA) decline was higher the group than that group, proportion a PSA ? 50% (p = 0.020). Radiological progression free (rPFS) overall (OS) significantly longer when compared < 0.001 p 0.027, respectively). In rPFS both pre- post-docetaxel settings 0.010 0.003, OS similar pre-docetaxel setting; but setting, had 0.021). multivariate analysis performed whole patient we found good for treatment, being 75 years while there factor OS. With PFS, seems be more suitable mCRPC setting AA.
منابع مشابه
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
BACKGROUND Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. METHODS Multicentre review of patients with mCRPC treated with abiraterone acetate and prednisone after progressing on enzalutamide. Primary objective was to determine...
متن کاملAbiraterone acetate: in metastatic castration-resistant prostate cancer.
Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone. In a pivotal phase III tr...
متن کاملAbiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel
Abiraterone acetate (AA) 1000-mg daily, a selective irreversible androgen biosynthesis inhibitor of cytochrome P450 c17 (CYP17) enzyme, is used in combination with prednisone 10-mg daily to treat docetaxel-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Several studies have demonstrated the safety and efficacy of this compound in men with mCRPC. Interim results fr...
متن کاملIndirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
This study was designed to evaluate the efficacy, tolerability, and sequential administration of abiraterone acetate (AA) and enzalutamide (Enz) for metastatic castration-resistant prostate cancer (mCRPC). A literature search was performed with PubMed, Embase, and Web of Science databases to identify relevant studies. Reviewed literature included published phase III trials of AA or Enz in mCRPC...
متن کاملAbiraterone acetate in the treatment of metastatic castration-resistant prostate cancer: review of clinical data
Abiraterone acetate (AA), after metabolization to abiraterone, is an oral inhibitor of the cytochrome P450C17 (CYP17) complex. It inhibits the production of androgens by interfering with the enzymes C17a hydroxylase and C17-C20 lyase. It was tested in patients with metastatic castration-resistant prostate cancer and showed promising results in Phase I and II studies with prostate specific antig...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Scientific Reports
سال: 2021
ISSN: ['2045-2322']
DOI: https://doi.org/10.1038/s41598-021-93659-x